<DOC>
	<DOCNO>NCT00356005</DOCNO>
	<brief_summary>The purpose study investigate efficacy azithromycin combination therapy artesunate treatment uncomplicated falciparum malaria Bangladesh .</brief_summary>
	<brief_title>Azithromycin Combination Therapy Treatment Uncomplicated Falciparum Malaria Bangladesh</brief_title>
	<detailed_description>In view spread antimalarial drug resistance urgent need new combination treatment disease kill one million people every year . Azithromycin macrolide antibiotic particularly attractive due safety child experience use pregnancy . Recent trial suggest azithromycin strong potential antimalarial . The purpose study investigate efficacy azithromycin combination therapy treatment uncomplicated falciparum malaria Bangladesh .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>1 . Acute symptomatic falciparum malaria infection parasite density 100 100,000 asexual parasites/uL determine screen smear fever ( defined ≥37.5ºC ) , report history fever within last 48 hour . 2 . Age : 865 year old 3 . Males female . All female age 12 require negative human chorionic gonadotropin ( hCG ) pregnancy test ( urine ) . All female childbearing potential ( surgically sterile , less two year menopausal ) require use acceptable method contraception , implant , injectable , oral contraceptive ( ) additional barrier contraception , intrauterine device , sexual abstinence , vasectomized partner , throughout study 4 . Written inform consent obtain 5 . Willing stay close medical supervision study duration 6 . Otherwise healthy outpatient 1 . Pregnant woman , nurse mother , woman childbearing potential use acceptable method contraception ( describe Inclusion Criteria , # 3 ) 2 . Mixed malaria infection admission malaria smear 3 . A previous history intolerance hypersensitivity study drug artesunate , azithromycin , lumefantrine drug similar chemical structure 4 . Malaria drug therapy administer past 30 day history 5 . Previous participation trial , participation study involve investigational market product , concomitantly within 30 day prior entry study 6 . History significant cardiovascular , liver renal functional abnormality clinically significant illness , opinion investigator would place increase risk . 7 . Symptoms severe vomit ( food inability take food previous 8 hour ) . 8 . Signs symptom severe malaria ( define WHO 2003 ) 9 . Unable and/or unlikely comprehend and/or follow protocol</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>falciparum malaria</keyword>
	<keyword>therapy</keyword>
	<keyword>azithromycin</keyword>
	<keyword>artesunate</keyword>
	<keyword>Coartem</keyword>
	<keyword>Bangladesh</keyword>
</DOC>